CASSAVA SCIENCES INC. - COMMON STOCK

Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press

12 Oct 2023 20:43:21 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY

05 Oct 2023 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

02 Oct 2023 06:00:44 By Nasdaq GlobeNewswire

Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease

18 Sep 2023 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

11 Sep 2023 06:10:00 By Nasdaq GlobeNewswire

Cassava Sciences Invited to Present in Four Upcoming Investor Conferences

06 Sep 2023 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

03 Aug 2023 06:07:00 By Nasdaq GlobeNewswire

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

05 Jul 2023 06:15:00 By Nasdaq GlobeNewswire

New Research Shows Simufilam Suppresses Overactive mTOR

27 Jun 2023 06:15:00 By Nasdaq GlobeNewswire

New Publication Highlights Basic Science Supporting Simufilam

12 Jun 2023 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the Jefferies Global Healthcare Conference

01 Jun 2023 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease

11 May 2023 06:15:00 By Nasdaq GlobeNewswire

New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A

08 May 2023 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates

01 May 2023 06:00:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference

26 Apr 2023 06:12:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

28 Feb 2023 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

08 Feb 2023 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

24 Jan 2023 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD

20 Dec 2022 06:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

06 Dec 2022 06:15:00 By Nasdaq GlobeNewswire